PLK1 and non-small cell lung carcinoma: The findings from our study both confirm and expand on previous preclinical studies, by demonstrating that targeting Plk1 with the small molecule inhibitor volasertib in combination with radiotherapy is a promising strategy for the treatment of NSCLC patients with functional p53.